Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) CEO Christopher Kroeger sold 34,411 shares of Maplight Therapeutics stock in a transaction on Friday, May 8th. The stock was sold at an average price of $27.69, for a total value of $952,840.59. Following the sale, the chief executive officer owned 1,526,309 shares in the company, valued at $42,263,496.21. This trade represents a 2.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Maplight Therapeutics Price Performance
Shares of NASDAQ:MPLT opened at $30.30 on Wednesday. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $33.28. The company has a market cap of $1.29 billion and a P/E ratio of -0.76. The company has a fifty day simple moving average of $23.54.
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). On average, sell-side analysts forecast that Maplight Therapeutics, Inc. will post -3.96 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on MPLT shares. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating for the company. Needham & Company LLC started coverage on Maplight Therapeutics in a research note on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price objective on the stock. HC Wainwright began coverage on Maplight Therapeutics in a report on Monday, May 4th. They set a “buy” rating and a $45.00 price objective for the company. Wall Street Zen downgraded Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, TD Cowen started coverage on Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.43.
Read Our Latest Stock Report on MPLT
Maplight Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Featured Articles
- Five stocks we like better than Maplight Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
